Difference between revisions of "Rilotumumab (AMG-102)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "/abstract " to " ") |
m |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 6: | Line 6: | ||
===[[Non-small cell lung cancer]]=== | ===[[Non-small cell lung cancer]]=== | ||
| − | # Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer. 2017 Aug 1;123(15):2936-2944. Epub 2017 May 4 [https:// | + | # Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer. 2017 Aug 1;123(15):2936-2944. Epub 2017 May 4 [https://doi.org/10.1002/cncr.30717 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517339/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28472537/ PubMed] |
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' AMG 102 | + | *'''Code name:''' AMG-102 |
[[Category:Drugs]] | [[Category:Drugs]] | ||
Latest revision as of 21:44, 7 July 2024
Mechanism of action
From the NCI Drug Dictionary: A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Rilotumumab binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. Route: IV
Preliminary data
Non-small cell lung cancer
- Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer. 2017 Aug 1;123(15):2936-2944. Epub 2017 May 4 link to original article link to PMC article PubMed
Also known as
- Code name: AMG-102